R.M. (Ric) Rumble, Director, President and Chief Executive Officer, TSO3

Richard (Ric) M. Rumble, President and Chief Executive Officer of TSO3Inc., joined the Company in October 2008. Prior to this appointment, he had accumulated more than 25 years of experience within the North American and global medical device industry. His impressive track record in the healthcare sterilization market and within the medical device industry includes delivering significant and sustained revenue and earnings growth, leading successful new commercial strategies, and negotiating and integrating large-scale acquisitions.

Mr. Rumble holds a BSc degree in biology and an Honours BSc in microbiology and immunology from the University of Western Ontario in London, Ontario. Prior positions held by Mr. Rumble include President of BERCHTOLD Corporation; Vice President, Sales & Marketing for Strategic Diagnostics Inc.; Vice President and General Manager of STERIS Corporation; and President and Chief Executive Officer of MediVators Inc. In addition, Mr. Rumble held a number of domestic and international management positions at 3M Company, including Global Business Unit Manager for Sterile Processing.

Glen Kayll, Chief Financial Officer

Glen Kayll, Chief Financial Officer of TSO3 Inc., joined the Company in December 2015. Mr. Kayll brings to TSO3 more than 20 years of senior management experience, including as CFO and head of operations for both Canadian and U.S. public companies listed on the TSX and NASDAQ exchanges. He has lead large teams through significant corporate transactions, including more than $4 billion in mergers and acquisitions, financings and other transactions during his career. Mr. Kayll was previously CFO of Argex Titanium, a TSX-traded, development-stage producer of high grade titanium dioxide (TiO2), which during his tenure secured a major partnership with the third largest chemical distributor in the world. Earlier he served as CFO and vice president of international operations for Coastal Contacts, a TSX and NASDAQ-traded, vertically integrated multinational manufacturer and internet retailer. Before Coastal, he was treasurer and head of investor relations at PMC-Sierra, a NASDAQ-listed, semiconductor and software solutions innovator which later became an S&P 500 component company.

Mr. Kayll holds a Bachelor of Commerce degree from Carleton University, an MBA from Simon Fraser University, and is a CPA.

Harold Tessman, Chief Operations Officer

Mr. Harold Tessman has more than 30 years of operational experience at industrial, consumer products and service organizations. His background includes extensive experience in operations, supply chain management, organizational development and M&A, as well as experience in the manufacturing of sterilizers and other medical devices. Mr. Tessman served as managing director and senior consultant for 10 years with TBM Consulting Group, a global operations management consulting firm. At TBM, he was a trusted advisor to Fortune 500 companies, private equity firms, and various multinational companies involved in medical device, pharma and other industries. In particular, Tessman oversaw the start-up phase of a global medical device company’s manufacturing plant, including materials management, scheduling, quality assurance and processes related to the production of medical equipment.

Mr. Tessman holds an MBA in Finance from Michigan State University and a Bachelor of Arts in International Studies and Economics from James Madison College.

Bradley J. Catalone, Chief Scientific Officer

Dr. Catalone has extensive knowledge of medical devices and the sterilization industry, having held significant roles within Olympus Corporation of the Americas Inc., including as Infection Control Manager, Director of Research, as well as Director of Clinical Affairs.  Most recently, Dr. Catalone held the position of Vice President of Laboratory Services at Alcami Corporation with responsibility for drug development and analytical testing services.

Dr Catalone holds a Ph.D. in Microbiology and Immunology from Penn State College of Medicine, Hershey, PA and an MBA. in Business Administration from the Pennsylvania State University.

Dr. Linda Rosenstock, Director, Chairperson of the Board

Dr. Rosenstock is a well-recognized physician executive in academia and government, with broad experience in clinical care, health care delivery, population health, research and health and regulatory policy.  She is Dean Emeritus, UCLA Fielding School of Public Health and is currently Professor of Health Policy and Management, Environmental Health Sciences and Medicine at UCLA. Dr. Rosenstock is the former Director of the National Institute for Occupational Safety and Health (NIOSH) and serves on a number of publicly traded and private corporate and non-profit boards of directors in the medical field.  She received her M.D. and M.P.H. from The Johns Hopkins University and is a recipient of the Presidential Distinguished Executive Rank Award, the highest executive service award in the US Government.

Dr. Douglas Dieter, Director

Dr. Dieter is currently a Managing Director at Ares Management, an asset manager headquartered in Los Angeles, CA, where he is responsible for investments across the healthcare spectrum, including inpatient and outpatient healthcare services, health insurers, medical device and pharmaceutical and biotech companies. Prior to joining Ares Management in 2016, Dr. Dieter was a Senior Analyst at Western Asset Management Company, an asset manager based in Pasadena, CA, where he was responsible for healthcare and technology high yield and loan investments. At Ares Management and Western Asset Management, his primary focus has been to provide capital solutions and financing for healthcare M&A and leveraged buyouts. He is a recognized authority on healthcare finance and has deep knowledge of the healthcare system, including Medicare and Medicaid payment systems.

Before entering the capital markets, Dr. Dieter served as a consultant to numerous start-up healthcare companies and non-profit healthcare institutions in Louisiana, Virginia, and Maryland. He is also the past Co-Chairman of the BioMedTech Committee for the Northern Virginia Technology Council and a past Board member for the Institute for New Medicine, a non-profit focused on HIV/AIDS research.

Dr. Dieter received his B.S. from Villanova University in Chemistry, his M.S. from Georgetown University in Chemistry, and an MPH and Dr. Ph. in Health Systems Management from Tulane University School of Public Health and Tropical Medicine. He has served as a commentator on CNBC’s Closing Bell, and in Forbes Magazine, Bloomberg News, The Wall Street Journal, as well as numerous other media outlets.

Martin J. Madden, Director

Mr. Madden has a broad background in medical device innovation and new product development.  Mr. Madden spent thirty years with Johnson & Johnson’s Medical Device organization, and, as an executive and a vice-president of Johnson & Johnson, Martin served on the management boards of Johnson & Johnson’s Global Surgery Group, Ethicon, Ethicon Endo-Surgery, DePuy-Synthes, and Cordis, and was also Chairman of Johnson & Johnson’s Medical Device Research Council, with responsibility for talent strategy and technology acceleration.  Martin’s leadership experiences spanned internal start-ups, executing turn-around’s, and leading large portfolio and technology intensive research organizations.

Mr. Madden graduated from Columbia University’s MBA program. He has a master’s degree in Mechanical Engineering from Carnegie-Mellon University and a bachelor’s degree in Mechanical Engineering from the University of Dayton.

Claude Michaud, Director, Chairperson Audit and Risk Management Committee

Mr. Claude Michaud, Currently Managing Director of DNA Capital, is an experienced finance executive and investment banker. After a 15-year career in investment banking with Scotia Capital and TD Securities, he became Chief Financial Officer of C-MAC Industries, Neurochem, Kangaroo Media and Groupe Lagassé. Mr. Michaud brings to the Board of Directors of TSO3 his expertise in corporate finance, mergers and acquisitions and corporate development.  He is also a member of the Board of Directors of Milit-Air, Corporation Financière Banque Nationale and Fondation du Théâtre du Nouveau-Monde. He is a past member of the Board of Directors of Andromed, Investment Dealers Association (Québec), Board of Trade of Metropolitan Montréal and the Women’s Y Foundation.

Mr. Michaud holds a Bachelor degree in engineering from McGill University and a MBA from Cornell University’s Johnson Graduate School of Management.

Jeffrey Pompeo, Director, Chairperson Human Resources Committee

Mr. Pompeo brings over 25 years of experience in high-growth medical device and technology companies.  He has lead several technology-driven businesses from inception through commercialization, and is well versed in strategic planning, business development, operational execution, and regulatory strategies in the United States and globally.  Mr. Pompeo is currently President & CEO of CareTaker Medical Corporation, a privately held wireless patient monitoring medical device company headquartered in the United States, and has served in senior executive and board director positions in numerous multinational organizations.  He holds a Computer Information Systems degree from James Madison University and an M.B.A. from Virginia Tech’s Pamplin College of Business.

Jean-Pierre Robert, Director

Mr. Jean-Pierre Robert brings to TSO3’s Board of Directors over 30 years of senior management experience in the global healthcare industry, in particular in diagnostics, specialty pharmaceuticals and medical imaging. After working at Fisher Scientific Ltd. as Executive Vice President, Eastern Canada and Vice President Marketing, he held, from 1996 to 2001 the position of Vice President and General Manager at Mallinckrodt Canada Inc., which was acquired by Tyco Healthcare in 2001. Most recently (2005-2010), he assumed the combined positions of President and CEO of Draximage, and Chief Operating Officer of the parent company Draxis Specialty Pharmaceuticals Inc., which was later acquired in 2010 by Jubilant Organosys, a privately owned company headquartered in India.

Throughout his career, Mr. Robert achieved many global business reorganizations with ramifications in North America, Europe and Asia, R&D portfolio realignments, merger & acquisitions, operations optimization projects as well as several financing rounds. He is currently Chairman of the board and CEO of CADENS Medical Imaging, a privately owned company located in the Québec province.

Mr. Robert holds a BSc in Chemistry from the University of Montreal and studied at the MBA level at HEC Montreal. He is a member of the Ordre des chimistes du Québec, the Radiology Society of North America, the European Society of Clinical Radiology and the Investing Group “Anges Québec”.

R.M. (Ric) Rumble, Director, President and Chief Executive Officer, TSO3

Mr. Richard (Ric) M. Rumble, President and Chief Executive Officer of TSO3 Inc., joined the Company in October 2008. Prior to this appointment, he had accumulated more than 25 years of experience within the North American and global medical device industry. His impressive track record in the healthcare sterilization market and within the medical device industry includes delivering significant and sustained revenue and earnings growth, leading successful new commercial strategies, and negotiating and integrating large-scale acquisitions.

Mr. Rumble holds a BSc degree in biology and an Honours BSc in microbiology and immunology from the University of Western Ontario in London, Ontario. Prior positions held by Mr. Rumble include President of BERCHTOLD Corporation; Vice President, Sales & Marketing for Strategic Diagnostics Inc.; Vice President and General Manager of STERIS Corporation; and President and Chief Executive Officer of MediVators Inc. In addition, Mr. Rumble held a number of domestic and international management positions at 3M Company, including Global Business Unit Manager for Sterile Processing.

Steve West, Director, Chairperson Corporate Governance and Nominating Committee

Mr. Steve West brings to TSO3’s board of directors a wealth of strategic experience, including more than 30 years of public company experience in health and life sciences, nuclear industry, specialty chemicals and venture capital. Mr. West recently served as CEO of Nordion (TSX: NDN, NYSE: NDZ), a leading provider of medical isotopes and sterilization technologies. During his tenure as CEO, Mr. West lead Nordion’s $727 million sale to two buyers, Sterigenics, a global leader in sterilization services, and GTCR, a private equity firm, at a 12% premium to the market.

Prior to Nordion, Mr. West held senior positions with MDS, where he was responsible for all aspects of the company’s global operations and regulatory affairs before its sale to Nordion. He has also served as a senior partner at MDS Capital, president at Unilever Canada, and vice president at Diversey Corporation. Steve has a degree in Zoology from London University (UK) and completed postgraduate research in Biotechnology and for several years was a Brewmaster in the UK. He has been a member of the Canadian Council of Chief Executives and currently also serves as chairman of the board for two non-profits, the Ottawa Hospital Foundation and The Innovation Centre at Bayview Yards.

 

Audit Committee and Risk Management Committee Human Resources Committee Corporate Governance and Nominating Committee
Dr. Linda Rosenstock X
Dr. Douglas Dieter X X
Claude Michaud X
Jeffrey Pompeo X X
Jean-Pierre Robert X
Richard M Rumble
Steve West X X
The following charters and policies define our roles and responsibilities to stakeholders:

CHARTER OF THE BOARD OF DIRECTORS [PDF 57 KB]

CHARTER OF THE AUDIT AND RISK MANAGEMENT COMMITTEE [PDF 35 KB]

CHARTER OF THE CORPORATE GOVERNANCE AND NOMINATING COMMITTEE [PDF 28 KB]

CHARTER OF THE ADVISORY COMMITTEE [PDF 21 KB]

CHARTER OF THE HUMAN RESOURCES COMMITTEE [PDF 26 KB]

MANDATE OF THE CHAIRPERSON OF THE BOARD OF DIRECTORS [PDF 19 KB]

CODE OF ETHICS [PDF 29 KB]

COMMUNICATION POLICY [PDF 34 KB]

WHISTLE BLOWING POLICY [PDF 25 KB]

INSIDER TRADING POLICY [PDF 26 KB]

VOTING MAJORITY POLICY [PDF 19 KB]

ARTICLES OF TSO3 (available in French only)

BYLAWS OF TSO3 (available in French only)

ADVANCE NOTICE POLICY